Inclusion Criteria: Subjects are eligible if they meet all of the following criteria  Aged between 1 year and 17 years of age; >=7kg (the weight considered safe for administration of adrenaline autoinjector (e.g. Jext); Ethnic Chinese; and Confirmed diagnosis of peanut allergy as defined by a failed double-blind placebo-controlled food challenge (DBPCFC) with peanut and a serum peanut-specific IgE level of at least 0.35 kUA (allergen-specific unit) per liter according to ImmunoCAP (Thermo Fisher Scientific) at screening.  Exclusion Criteria: Subjects are not eligible if they meet any of the following criteria  History of severe anaphylaxis (as defined by persistent hypotension, collapse, loss of consciousness, persistent hypoxia or ever needing >3 doses of intramuscular adrenaline or an intravenous adrenaline infusion for management of an allergic reaction); Severe anaphylaxis during the study entry DBPCFC (defined as persistent hypotension, collapse, loss of consciousness, persistent hypoxia, or requiring >3 doses of intramuscular adrenaline or an intravenous adrenaline infusion for management of an allergic reaction); FEV1 <85% at rest and FEV1/FVC ≤ 85% at rest or ongoing chronic persistent asthma (as per Australian Asthma Foundation guidelines); Underlying medical conditions (e.g. cardiac disease) that increase the risks for anaphylaxis; Use of beta-blockers, and ACE inhibitors; Inflammatory intestinal conditions, indwelling catheters, gastrostomies, immunocompromised states, post-cardiac and/or gastrointestinal tract surgery, critically-ill or other conditions that may increase the risks of probiotic associated sepsis; Already taking probiotic supplements or foods containing probiotics within the past month; Reacting to the placebo component during the study entry DBPCFC; Have received other food immunotherapy treatment in the preceding 12 months; History of suspected or biopsy-confirmed eosinophilic esophagitis (EoE); Currently taking immunomodulatory therapy (including allergen immunotherapy); Past or current major illness that in the opinion of the Site Investigator may affect the subject's ability to participate in the study e.g. increased risk to the participant; Subjects who in the opinion of the Site Investigator are unable to follow the protocol; Another family member already enrolled in the trial (to maintain safety and blinding); or Non-English and non-Chinese speaking participants and their families. NOTE: participants with other food allergies are NOT excluded from participating in this trial.